Tolterodine for the treatment of urge urinary incontinence

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 14, 2013, Pages 1987-1991

  Elterman, Dean S ^a   Chughtai, Bilal ^a   Kaplan, Steven A ^a   Barkin, Jack ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Detrol; Incontinence; Overactive bladder; Tolterodine; Urge urinary incontinence

Indexed keywords

CYTOCHROME P450 2D6; DIURETIC AGENT; FESOTERODINE; FLUOXETINE; KETOCONAZOLE; LONG ACTING DRUG; MOXIFLOXACIN; ORAL CONTRACEPTIVE AGENT; OXYBUTYNIN; PLACEBO; SHORT ACTING DRUG; TOLTERODINE; WARFARIN; WATER;

ABDOMINAL PAIN; AGE DISTRIBUTION; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; BLADDER PRESSURE; CLOSED ANGLE GLAUCOMA; CONSTIPATION; DETRUSOR MUSCLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GERIATRIC PATIENT; HEART RATE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MICTURITION; MOLECULAR WEIGHT; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PKA; PLASMA CONCENTRATION-TIME CURVE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESIDUAL URINE; STEADY STATE; TORSADE DES POINTES; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CRESOLS; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; UROLOGICAL AGENTS;

EID: 84884220555     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.823158     Document Type: Article

References (20)

1. Rovner ES, Wein AJ, Caruso D. A woman's guide to regaining bladder control. In: Evans M, editor. Everything you need to know for the diagnosis and cure of incontinence. M evans and Company Incorporated, New York; 2002
2. Herschorn S, Gajewski J, Schulz J, Corcos J. A population-based study of urinary symptoms and incontinence: The canadian urinary bladder survey. BJU Int 2008;101(1):52-8
3. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: Aua/sufu guideline. J Urol 2012;188(6 Suppl):2455-63
4. Basra R, Kelleher C. Disease burden of overactive bladder: Quality-of-life data assessed using ici-recommended instruments. Pharmacoeconomics 2007;25(2):129-42
5. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997;26(5):367-74
6. Weiss JP, Weinberg AC, Blaivas JG. New aspects of the classification of nocturia. Curr Urol Rep 2008;9(5):362-7
7. Galizia G, Langellotto A, Cacciatore F, et al. Association between nocturia and falls-related long-term mortality risk in the elderly. J Am Med Dir Assoc 2012;13(7):640-4
8. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey. Value Health 2004;7(4):455-63
9. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
10. Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189(4):1388-95
11. Guay DR. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 1999;19(3):267-80
12. Detrol (Tolterodine L-Tartrate) Product Monograph. Pfizer Canada Inc., 17,300 Trans-Canada Highway. Kirkland Quebec h9j 2m5; February 10; 2010
13. Malhotra BK, Glue P, Sweeney K, et al. Thorough qt study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007l;81(3):377-85
14. Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase ii efficacy and safety data. Urology 1999;53(5):990-8
15. Van Kerrebroeck PE, Amarenco G, Thuroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17(5):499-512
16. DuBeau CE, Morrow JD, Kraus SR, et al. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn 2012;31(8):1258-65
17. Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 2011;37(8):1084-91
18. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999;161(5):1551-5
19. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997;50(6A Suppl):90-6; discussion 97-99
20. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001;2(10):1685-701